ABSTRACT
Although it was clear early on that mAbs can mediate killing of tumor or other cells through a variety of mechanisms—including complement activation, targeting NK cells, monocytes, and macrophages to mediate ADCC and/or phagocytosis, or by inducing apoptosis—the use of mAbs to treat human tumors or other diseases was not initially successful.
